Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : M42
Deal Size : Undisclosed
Deal Type : Series B Financing
Juvenescence Closes $76M Series B-1 Led by M42 with Strategic Partnership
Details : The financing will enable Juvenescence to continue advancing its portfolio of therapeutics into clinical development and deliver critical clinical readouts for its core medicine pipeline.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : M42
Deal Size : Undisclosed
Deal Type : Series B Financing